Patents Assigned to Pharmaceuticals, Inc.
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20130317001
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC.
    Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE
    Publication number: 20130316989
    Abstract: The invention relates to methods of treating inflammatory disease comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, or an oxylipin compound.
    Type: Application
    Filed: August 5, 2013
    Publication date: November 28, 2013
    Applicant: RESOLVYX PHARMACEUTICALS, INC.
    Inventor: Per Gjorstrup
  • SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
    Publication number: 20130317033
    Abstract: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?1-GABAA receptor antagonist or an ?2- and/or an ?3-GABAA receptor partial agonist.
    Type: Application
    Filed: August 5, 2013
    Publication date: November 28, 2013
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventors: Scott L. Harbeson, Roger Tung, Julie F. Liu
  • COMPOSITIONS AND METHODS UTILIZING POLY(VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUS
    Publication number: 20130316009
    Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles including pharmaceutical agents that have a low water/aqueous solubility. In some embodiments, a surface coating includes a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, such as poly(vinyl alcohol) (PVA). Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
    Type: Application
    Filed: May 3, 2013
    Publication date: November 28, 2013
    Applicant: KALA PHARMACEUTICALS, INC.
    Inventor: KALA PHARMACEUTICALS, INC.
  • Composition and Method for Treating Neurological Disease
    Publication number: 20130317115
    Abstract: A method of administering amantadine is provided. The method comprises orally administering to a subject a pharmaceutical composition comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of the amantadine. A dose of the composition provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the change in amantadine plasma concentration provided by a dose of the same quantity of an immediate release form of amantadine. The change in plasma concentration over time (dC/dT) is measured in a single dose human pharmacokinetic study in a defined time period of 0 to 4 hours after administration. The amantadine, or pharmaceutically acceptable salt thereof, is administered once daily at a dose of 300 to 500 mg per day.
    Type: Application
    Filed: August 2, 2013
    Publication date: November 28, 2013
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • OXYPYRIMIDINES AS SYK MODULATORS
    Publication number: 20130317029
    Abstract: The present invention is directed to compounds of formula (I) and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which arc inhibitor of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Application
    Filed: November 1, 2011
    Publication date: November 28, 2013
    Applicant: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Anjali Pandey, Qing Xu, Wolin Huang, Zhaozhong J. Jia, Yonghong Song
  • FATTY ACID CONJUGATES OF STATIN AND FXR AGONISTS; COMPOSITIONS AND METHOD OF USES
    Publication number: 20130316995
    Abstract: The invention relates to fatty acid statin conjugates and fatty acid FXR agonist conjugates; compositions comprising an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid statin conjugate or a fatty acid FXR agonist conjugate.
    Type: Application
    Filed: May 1, 2013
    Publication date: November 28, 2013
    Applicant: Catabasis Pharmaceuticals, Inc.
    Inventor: Catabasis Pharmaceuticals, Inc.
  • COMPOSITIONS AND METHODS FOR DELIVERING ESTRADIOL IN TRANSDERMAL DRUG DELIVERY SYSTEMS
    Publication number: 20130317461
    Abstract: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin.
    Type: Application
    Filed: December 14, 2012
    Publication date: November 28, 2013
    Applicant: Noven Pharmaceuticals, Inc.
    Inventors: David Kanios, Rod Hartwig
  • PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS
    Publication number: 20130316001
    Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
    Type: Application
    Filed: May 3, 2013
    Publication date: November 28, 2013
    Applicant: Kala Pharmaceuticals, Inc.
    Inventor: Kala Pharmaceuticals, Inc.
  • METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE INFECTIONS
    Publication number: 20130315863
    Abstract: A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Application
    Filed: July 31, 2013
    Publication date: November 28, 2013
    Applicants: Universita' degli Studi di Cagliari, Idenix Pharmaceuticals, Inc.
    Inventors: Jean-Pierre SOMMADOSSI, Paolo LaColla
  • NOVEL CRYSTALLINE FORMS
    Publication number: 20130316982
    Abstract: Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Application
    Filed: November 23, 2011
    Publication date: November 28, 2013
    Applicant: THAR PHARMACEUTICALS, INC.
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna, Paul K. Isbester, Xufeng Sun
  • BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS
    Publication number: 20130316979
    Abstract: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
    Type: Application
    Filed: July 30, 2013
    Publication date: November 28, 2013
    Applicant: ANACOR PHARMACEUTICALS, INC.
    Inventors: Stephen J. Baker, Virginia Sanders, Tsutomu Akama, Carolyn Bellinger-Kawahara, Yvonne Freund, Kirk R. Maples, Jacob J. Plattner, Yong-Kang Zhang, Huchen Zhou, Vincent S. Hernandez
  • Antibodies To Alpha-Synuclein
    Publication number: 20130317199
    Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.
    Type: Application
    Filed: March 18, 2011
    Publication date: November 28, 2013
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: TAMIE CHILCOTE, ROBIN BARBOUR
  • ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17
    Publication number: 20130317007
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: April 11, 2013
    Publication date: November 28, 2013
    Applicant: Reata Pharmaceuticals, Inc.
    Inventors: Eric ANDERSON, Xin JIANG, Melean VISNICK
  • BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20130316943
    Abstract: Disclosed herein are polybasic bacterial efflux pump inhibitors containing boronic acid functionality and their methods of synthesis, methods of use, and pharmaceutical compositions. Some embodiments include methods of treating or preventing a bacterial infection by co-administering to a subject infected with bacteria or at risk of infection with bacteria the efflux pump inhibitor with another anti-bacterial agent.
    Type: Application
    Filed: February 6, 2012
    Publication date: November 28, 2013
    Applicant: REMPEX PHARMACEUTICALS, INC.
    Inventors: Tomasz Glinka, Robert Higuchi, Scott Hecker, Brian Eastman, Olga Rodny
  • Cyclic carbazate and semicarbazide inhibitors of 11?-hydroxysteroid dehydrogenase 1
    Patent number: 8592409
    Abstract: This invention relates to novel compounds of the Formula (I), (Ia), (Ic), (Ie), (If), (Ig), (Ih), (Ii), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: November 26, 2013
    Assignee: Vitae Pharmaceuticals, Inc.
    Inventors: David A. Claremon, Linghang Zhuang, Yuanjie Ye, Suresh B. Singh, Colin M. Tice, Salvacion Cacatian
  • Deuterated darunavir
    Patent number: 8592487
    Abstract: This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel hydroxyethylamino sulfonamide derivatives that are derivatives of darunavir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a human immunodeficiency virus (HIV) protease inhibitor, such as darunavir.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: November 26, 2013
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Diazonamide analogs
    Patent number: 8592469
    Abstract: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.
    Type: Grant
    Filed: April 15, 2012
    Date of Patent: November 26, 2013
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Qi Wei, Ming Zhou, Xiaoming Xu, Charles Caldwell, Susan Harran, Lai Wang
  • Cloned glucagon-like peptide-2 receptors
    Patent number: 8592553
    Abstract: The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: November 26, 2013
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Donald G. Munroe, Ashwani K. Gupta, Tejal B. Vyas, Kirk McCallum, Ermei Fan
  • Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
    Patent number: 8591864
    Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: November 26, 2013
    Assignee: AMAG Pharmaceuticals, Inc.
    Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis